Johan Albrecht
Analyst · Credit Suisse. Your line is now open
Thank you, Fried. I’ll start with a brief review of our consolidated revenue on Slide 7. First. I’d like to remind everyone that when we refer to sales in our presentation, we mean revenues plus deferred revenues. Also please note that unless otherwise stated, all comparisons in this call are against our results for the same period in 2015. Finally, in each of the six slides I cover, I will focus on our results for the quarter. Although certain data for the year also are shown for reference. As Peter mentioned in his opening remarks, in this year's fourth quarter we generated a 12% increase in revenue, with increases in all of the segments. Materialise software accounted for 26% of our total revenue. Materialise medical for 32% and Materialise manufacturing for 42%. As you know, two of our Company's goals are to grow to the contribution -- to grow the contribution that software revenue and end parts revenue make to our total mix. In the fourth quarter of 2016, total revenue from software products rose by 2 percentage points to 39%, while end parts decreased by 1 percentage point to 37%. Prototyping accounted for 24% of total revenue as compared to 25%. Moving to Slide 8, you can see our consolidated adjusted EBITDA numbers for the fourth quarter. As Peter mentioned in his opening remarks, consolidated adjusted EBITDA increased by 50% growing from €2,979,000 to €4,455,000. Our adjusted EBITDA margin improved from 10.6% to 14.2%. This improvements primarily reflect two factors. First, our continued double-digit revenue growth. And second, a modest increase of only 3.6% in operational expenses. Slide 9, summarizes the results of our Materialise software segment. The revenue grew 11%, recurring sales grew 38% driven by 80% growth in sales generated from new annual licenses. The strong performance is not fully reflected in the revenues, but a significant portion of these sales have been deferred to the balance sheet. OEM sales grew 41% compared to last year's period. Despite continued initiatives in software development, mostly using corporate resources, segment EBITDA margin remained at 37%, on to 9 percentage EBITDA growth. Moving to Slide 10, you will see the total revenue in our Materialise medical segment grew 5% for the quarter. Medical software sales increased 30%, driven by 60% growth in sales generated from annual and renewal licenses. Just as in our software segment, an important portion of the sales could not be recognized in the period and is part of the increase of deferred revenues. Software revenues represented 40% of the total medical segment. The 83% increase from direct sales from complex surgery devices more than offset a 4 percentage decline in sales from collaborative medical devices. EBITDA for the medical segment was €656,000 compared to €747,000 in the prior-year period. The EBITDA was negatively affected by approximately €350,000 decrease in all the operating income mainly as a result of lower other operating income from governmental grants, while we increased the focus of our development efforts on business projects. Nevertheless, the segment EBITDA margin remained at approximately 7%. Now let’s turn to Slide 11, for an overview of the quarter four performance of our Materialise manufacturing segment. There, revenue rose 19% driven primarily by revenue from end part manufacturing, which was up 20% over last year's period. And parts accounted for 39% of the segments revenue, up from 37% last year. The Company's total number of printers rose slightly this quarter to 150 and includes a first HP Jet Fusion printer that became operational in the fourth quarter. Since the beginning of 2016, we added 12 printers. EBITDA rose from 1,033,000 to €1,438,000. The margin increased to 11% this quarter from 9% last year. The operations of i.materialise and RapidFit, which are becoming more mature that fully integrated in the fourth quarter in the Materialise manufacturing business lines in order to create additional synergies. Hence we will no longer refer to their EBITDA impact in our future earnings calls. Slide 12 provides the highlights of our income statement for the fourth quarter. Gross profit rose 12% compared to last year's period, while gross margin was stable at 59%. In total, R&D, sales and marketing, and G&A spending rose by 3.6% over the prior-year period. Sales and marketing and G&A each increased slightly, while R&D decreased modestly. Our G&A increased primarily reflected the managerial structure and support we have been implementing within our sales and marketing and R&D groups. As I will repeat for the last time in this earnings call, a number of employees within these groups have evolved into more managerial or administrative roles and the costs as well as certain other expenses are now categorized under G&A. Although income net decreased by 500 -- €400,000 to €1.8 million. Net other operating income consists primarily of withholding tax exemptions for qualifying researches, development grounds, partial funding of R&D projects, and currency exchange on purchase and sales transactions. There are always some moving parts in these competence, but among other things quarter four was affected by a decrease in government grants for specific research programs. As I mentioned earlier, our development initiatives have been focused more on business projects that are mostly not sponsored by specific governmental grants. We posted an operating profit of €1,915,000 compared to €932,000 for the fourth quarter of 2015, an improvement of almost €1 million. Net financial result was €253,000 compared to €356,004 for last year's period, reflecting smaller variances in the currency exchange rate, primarily on the portion of the Company's IPO proceeds held in U.S dollar. Net profit for the fourth quarter of 2016 was €620,000 compared to a net profit of €2.1 million for last year's period. The operating profit improvement was offset by the movement in income tax from an income of €1,010,000 last year to a cost of almost €900,000, affected by variances and deferred taxes which have no cash in effect. And the increase also in our share in the loss of the joint venture of RSPrint from €153,000 to €650,000. Now please turn to Slide 13 for a recap of balance sheet and cash flow highlights. Our balance sheet remains strong with debt accounting for 21% of total liabilities and equity at year end. For the full-year 2016, total loans and borrowings increased by €12.7 million to €33.8 million and are all asset based. Capital expenditures amounted to €6.9 million compared to €3.6 million for the last quarter last year. Cash flow from operations was €4,180,000 compared to €724,000 last year. For the full-year, cash flow from operations amounted €8.4 million. We ended the quarter with cash and cash equivalents, including held to maturity investments of €55.9 million compared to €50.7 million as of December 31, 2015. Total deferred income amounted to €21.4 million compared to €16.6 million at the end of last year. The deferred annual software sales and maintenance contracts rose to €16.8 million from €13.1 million 12 months ago. And with that overview, I will turn the call back to Peter.